NR1H4 and metabolic dysfunction-associated steatotic liver disease: More research is ongoing to explore the possible use of PPAR ligands, miRNA, glucagon-like peptide (GLP) analogues, farnesoid X receptor (FXR) agonists, chemokine receptor (CCR)2/CCR5 antagonists, probiotics, antibiotics, vitamin E, and statins in the management of NAFLD [19].